This study was designed to evaluate the safety and efficacy of fruquintinib plus trastuzumab, and XELOX as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Have fully understood the study and voluntarily signed the informed consent;
18-75 years old (including 18 and 75 years old);
Pathologically determined advanced gastric or gastroesophageal junction adenocarcinoma;
No previous anti-tumor treatment for metastatic diseases;
Failure to comply with the study protocol or study procedure;
Previous treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors, chemotherapy or immune checkpoint inhibitors;
Have had other malignancies within the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;
Known presence of symptomatic central nervous system metastasis or brain metastases;
Henan Cancer Hospital
Lead sponsor